The evidence covered by this review indicates that PPARγ agonists act simultaneously on several cellular metabolism and repair processes in the CNS that become dysfunctional because of cellular damage caused by neuroinflammatory and neurodegenerative diseases. Here, PPARG is linked to neurodegenerative disease.